A federal appeals court is today due to again deliberate on whether it's possible to patent isolated human genes in a case that will probably have wide ramifications for the development of medical tests and treatments. The case involves Myriad Genetics (MYGN), which holds patents - at the moment - that allow it to genetically screen those at risk of breast or ovarian cancer.
A federal appeals court is today due to again deliberate on whether it's possible to patent...
From other sites
Video at CNBC.com (Sep 15, 2015)
at CNBC.com (Oct 17, 2014)
at CNBC.com (Aug 13, 2014)
at CNBC.com (Aug 12, 2014)
at CNBC.com (Apr 11, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs